Jump Financial LLC Boosts Position in Cellebrite DI Ltd. $CLBT

Jump Financial LLC boosted its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 46.8% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 206,965 shares of the company’s stock after purchasing an additional 65,965 shares during the quarter. Jump Financial LLC owned approximately 0.09% of Cellebrite DI worth $4,021,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Teacher Retirement System of Texas boosted its position in Cellebrite DI by 121.3% during the first quarter. Teacher Retirement System of Texas now owns 44,407 shares of the company’s stock worth $863,000 after purchasing an additional 24,337 shares in the last quarter. California State Teachers Retirement System boosted its position in Cellebrite DI by 19.3% during the fourth quarter. California State Teachers Retirement System now owns 71,385 shares of the company’s stock worth $1,573,000 after purchasing an additional 11,555 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Cellebrite DI in the first quarter valued at $269,000. Bank of America Corp DE boosted its stake in shares of Cellebrite DI by 32.0% during the fourth quarter. Bank of America Corp DE now owns 680,375 shares of the company’s stock valued at $14,989,000 after acquiring an additional 165,116 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Cellebrite DI by 32.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 148,132 shares of the company’s stock valued at $3,263,000 after acquiring an additional 36,341 shares during the last quarter. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on CLBT. Lake Street Capital cut their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, August 15th. JPMorgan Chase & Co. cut their target price on shares of Cellebrite DI from $29.00 to $25.00 and set an “overweight” rating for the company in a research note on Monday, May 12th. Wall Street Zen raised shares of Cellebrite DI from a “hold” rating to a “buy” rating in a research note on Saturday, August 16th. Finally, Needham & Company LLC cut their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, August 14th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $22.40.

Cellebrite DI Trading Down 1.7%

NASDAQ CLBT opened at $15.83 on Tuesday. The business’s 50-day moving average price is $14.94 and its 200 day moving average price is $17.35. Cellebrite DI Ltd. has a twelve month low of $13.10 and a twelve month high of $26.30. The company has a market capitalization of $3.79 billion, a PE ratio of -20.83, a price-to-earnings-growth ratio of 3.19 and a beta of 1.27.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The firm had revenue of $113.28 million for the quarter, compared to the consensus estimate of $112.33 million. During the same period in the prior year, the business posted $0.10 earnings per share. The firm’s revenue for the quarter was up 18.4% compared to the same quarter last year. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.